Compare DSP & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DSP | OBIO |
|---|---|---|
| Founded | 1999 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 213.3M | 246.2M |
| IPO Year | 2021 | 2020 |
| Metric | DSP | OBIO |
|---|---|---|
| Price | $11.65 | $4.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $18.11 | $14.25 |
| AVG Volume (30 Days) | ★ 218.4K | 211.4K |
| Earning Date | 03-11-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 157.14 | 33.13 |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $344,201,000.00 | $33,482,000.00 |
| Revenue This Year | $16.52 | N/A |
| Revenue Next Year | $16.62 | N/A |
| P/E Ratio | $32.92 | ★ N/A |
| Revenue Growth | 19.00 | ★ 1169.22 |
| 52 Week Low | $8.11 | $2.20 |
| 52 Week High | $16.25 | $5.42 |
| Indicator | DSP | OBIO |
|---|---|---|
| Relative Strength Index (RSI) | 58.72 | 54.29 |
| Support Level | $11.09 | $4.08 |
| Resistance Level | $12.63 | $4.88 |
| Average True Range (ATR) | 0.86 | 0.31 |
| MACD | 0.20 | 0.00 |
| Stochastic Oscillator | 63.54 | 60.90 |
Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. It operates a cloud-based demand side platform ("DSP") that is used by marketers and its advertising agencies to centralize the planning, buying and measurement of its advertising across channels, including connected TV (CTV), streaming audio, digital out-of-home, mobile and desktop.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.